Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-617-1309
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.43 million
Profitability
Miscellaneous
Employees290
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?
Melinta Therapeutics shares reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($2.34) EPS for the quarter, topping the consensus estimate of ($2.72) by $0.38. The biotechnology company earned $14.08 million during the quarter, compared to the consensus estimate of $16.83 million. Melinta Therapeutics had a negative return on equity of 61.13% and a negative net margin of 161.27%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
7 analysts have issued 1 year target prices for Melinta Therapeutics' shares. Their predictions range from $5.00 to $70.00. On average, they expect Melinta Therapeutics' share price to reach $32.10 in the next twelve months. This suggests a possible upside of 538.2% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Melinta Therapeutics.
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month price target of $15 for MLNT shares. We continue to believe that upward earnings revisions and multiple expansion, from the uptake of its drugs, will drive the stock higher." (5/9/2019)
- 2. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (2/27/2019)
Has Melinta Therapeutics been receiving favorable news coverage?
News stories about MLNT stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Melinta Therapeutics earned a news impact score of 1.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Melinta Therapeutics.
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a decrease in short interest in May. As of May 31st, there was short interest totalling 1,810,300 shares, a decrease of 10.0% from the April 30th total of 2,010,900 shares. Based on an average daily volume of 482,000 shares, the short-interest ratio is presently 3.8 days. Currently, 25.5% of the company's shares are short sold. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Syndax Pharmaceuticals (SNDX), Lannett (LCI), Five Prime Therapeutics (FPRX), Abeona Therapeutics (ABEO), Kadmon (KDMN), Recro Pharma (REPH), American Brivision (Holding) (ABVC), Kamada (KMDA), Avid Bioservices (CDMO), MannKind (MNKD), Cerecor (CERC), Affimed (AFMD), Marinus Pharmaceuticals (MRNS), Bicycle Therapeutics (BCYC) and Aldeyra Therapeutics (ALDX).
What other stocks do shareholders of Melinta Therapeutics own?
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
- Mr. John H. Johnson, CEO & Director (Age 61)
- Dr. Thomas A. Steitz, Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen, Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (3.66%), Isthmus Partners LLC (0.75%), Spark Investment Management LLC (0.40%), Boenning & Scattergood Inc. (0.31%), Franklin Street Advisors Inc. NC (0.12%) and Creative Planning (0.10%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which institutional investors are selling Melinta Therapeutics stock?
Which institutional investors are buying Melinta Therapeutics stock?
MLNT stock was acquired by a variety of institutional investors in the last quarter, including Isthmus Partners LLC and Algert Global LLC. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $5.03.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $59.25 million and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.View Additional Information About Melinta Therapeutics.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD SUITE 280, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
